Rockwell Medical Acknowledges Receipt of Communications from Medical Resource Acquisition Group
March 10 2020 - 6:50AM
Rockwell Medical, Inc. (NASDAQ:RMTI) (“Rockwell Medical” or the
“Company”), a biopharmaceutical company dedicated to transforming
anemia management and improving outcomes for patients around the
world, today issued the following statement in response to
communications publicly disseminated yesterday by an entity named
“Medical Resource Acquisition Group LLC” (MRAG), which purports to
be a Rockwell Medical stockholder.
The Company issued the following statement:
“Rockwell Medical has received certain email
communications from an entity named “Medical Resource Acquisition
Group LLC”, which purports to be a Rockwell Medical stockholder
owning 10,000 shares and seeking to nominate three individuals for
election to our Board at the 2020 annual meeting of stockholders.
The Board of Directors is in the process of reviewing the materials
submitted by MRAG. Stockholders do not need to take any action at
this time.”
The 2020 annual meeting of Rockwell Medical
stockholders has not yet been scheduled. The Company’s Board of
Directors will present its formal recommendation to stockholders
regarding director nominations in the Company’s proxy
statement.
Gibson, Dunn & Crutcher LLP is acting as legal
counsel to Rockwell Medical.
About Rockwell Medical
Rockwell Medical is a biopharmaceutical company
dedicated to transforming anemia management in a wide variety of
therapeutic areas and across the globe, improving the lives of very
sick patients. The Company’s initial focus is the treatment of
anemia in end-stage renal disease (ESRD). Rockwell Medical's
exclusive renal drug therapy, Triferic (ferric pyrophosphate
citrate), is the only FDA-approved therapeutic indicated for iron
replacement and maintenance of hemoglobin in hemodialysis patients.
The Company has developed multiple formulations of Triferic (1)
FDA-approved Dialysate Triferic, and (2) I.V. Triferic, for which
the Company filed a New Drug Application in May 2019. Rockwell
Medical is also an established manufacturer, supplier and leader in
delivering high-quality hemodialysis concentrates/dialysates to
dialysis providers and distributors in the U.S. and abroad.
Triferic® is a registered trademark of Rockwell
Medical, Inc.
Forward-Looking Statements
This press release may contain statements which may
be considered forward-looking within the meaning of the U.S.
federal securities laws. These statements are subject to known and
unknown risks, uncertainties and other factors that may cause our
actual results, performance or achievements to differ materially
from results expressed or implied in this press release. Additional
information is contained in the Risk Factors sections of Rockwell
Medical’s most recent reports filed with the SEC on Form 10-K and
Form 10-Q. Rockwell Medical does not intend to update these
forward-looking statements as a result of future events or
developments.
ContactInvestor Relations: Lisa M.
Wilson, In-Site Communications, Inc. T: 212-452-2793 E:
lwilson@insitecony.com
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Rockwell Medical (NASDAQ:RMTI)
Historical Stock Chart
From Apr 2023 to Apr 2024